Close Menu

NEW YORK ─ Auckland, New Zealand-based Pictor is eyeing international expansion with a multiplexed microarray immunoassay to detect different stages of SARS-CoV-2 at the point of care.

The test, which is in development, may determine intermediate stages of COVID-19 that are not currently detectable and could give clinicians greater insight into how to better treat their patients, the firm's newly appointed CEO Thomas Schlumpberger said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.